Clinical Analysis of Triple Therapy in the Treatment of Helicobacter Pylori-related Gastritis

ZOU Qing-wei

doi:10.14033/j.cnki.cfmr.2015.01.001

Abstract：Objective:To observe the curative effect of Omeprazole and Esomeprazole triple therapy for Helicobacter pylori(Hp) associated gastritis. Method:280 Hp positive patients with chronic gastritis in our hospital from June 2013 to May 2014 were selected,they were divided into the Omeprazole group and the Esomeprazole group according to the random number table method,140 cases in each group.The Omeprazole group was taken with Omeprazole, Amoxicillin and Levofloxacin for treatment.The Esomeprazole group was taken with Esomeprazole,Amoxicillin and Levofloxacin for treatment.The Hp cure rates and differences in clinical symptoms and histological improvement between the two groups were observed and compared.Result:Hp eradication rate of the Esomeprazole group was 81.43%(114/140),which was significantly higher than 69.29%(97/140) of the Omeprazole group,the clinical control rate and total effective rate of clinical symptoms improvement in the Esomeprazole group were 22.86%and 92.14%,which were significantly higher than 14.29%and 76.43%in the Omeprazole group,the clinical control rate and total effective rate of histological improvement in the Esomeprazole group were 29.29%and 65.00%,which were significantly higher than 17.86%and 50.71%in the Omeprazole group,the differences were statistically significant(P<0.05).Conclusion:The Esomeprazole triple therapy in the treatment of Helicobacter pylori-associated gastritis can effectively improve the Hp eradication rate,promote the improvement of clinical symptoms and pathological histology,and its curative effect is better than that of omeprazole triple therapy,is worthy of clinical promotion.